Ascentage Pharma Group Internat (AAPG)Healthcare | Biotechnology | Suzhou, China | NasdaqGM
19.60 USD
-0.37
(-1.853%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 19.60 -0.02 (-0.020%) ⇩ (July 13, 2026, 4:10 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:12 a.m. EDT
The immediate outlook is neutral despite a recent bounce; the stock has recovered slightly from its lows but remains significantly below its 200-day average, indicating the broader downtrend has not yet reversed. While the 45-day statistical model offers a weak bearish lean, it lacks the confidence to override the mixed technical picture where volume is well below average. Long-term, the investment case is currently stalled by severe financial distress rather than a lack of potential. Although the company boasts exceptional top-line growth with revenue surging 117% year-over-year and a robust gross margin above 90%, these positives are completely negated by a catastrophic operating burn rate and negative free cash flow exceeding $900 million. The balance sheet is fragile, with debt nearly matching cash reserves and a negative return on equity of over 150%. The market has correctly priced this as a high-risk turnaround story; the negative forward P/E and the fact that the price is trading at nearly 9.5 times book value suggest investors are demanding a massive premium for the risk of capital dilution or bankruptcy before any value can be realized. Without a clear path to profitability or a confirmed major acquisition, the fundamentals do not support a buy-and-hold thesis. |
| Model | MAE |
|---|---|
| MSTL_41 ✓ | 0.230828 |
| MSTL | 0.248378 |
| AutoETS | 0.257974 |
| AutoARIMA | 0.257975 |
| AutoTheta | 0.270196 |
Forecast horizon: 60 days | Selected: MSTL_41
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 13.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.248 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 148.381 |
| Revenue per Share | 6.448 |
| Market Cap | 1,829,409,408 |
| Forward P/E | -16.47 |
| Beta | 0.66 |
| Profit Margins | -216.47% |
| Website | https://www.ascentage.cn |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.44834256 |
| Address1 | Suzhou Industrial Park |
| Address2 | 68 Xinqing Road |
| All Time High | 48.45 |
| All Time Low | 16.36 |
| Ask | 23.14 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 27,630 |
| Average Daily Volume3 Month | 10,983 |
| Average Volume | 10,983 |
| Average Volume10Days | 27,630 |
| Beta | 0.659 |
| Bid | 17.87 |
| Bid Size | 5 |
| Book Value | 2.102296 |
| City | Suzhou |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.6 |
| Current Ratio | 1.792 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 19.62 |
| Day Low | 19.482 |
| Debt To Equity | 148.381 |
| Display Name | Ascentage Pharma |
| Earnings Call Timestamp End | 1,774,555,200 |
| Earnings Call Timestamp Start | 1,774,555,200 |
| Earnings Timestamp End | 1,774,468,800 |
| Earnings Timestamp Start | 1,774,468,800 |
| Ebitda | -1,137,625,984 |
| Ebitda Margins | -1.98151 |
| Enterprise To Ebitda | -1.172 |
| Enterprise To Revenue | 2.323 |
| Enterprise Value | 1,333,507,456 |
| Eps Current Year | -1.51619 |
| Eps Forward | -1.19 |
| Eps Trailing Twelve Months | -2.05 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.18264 |
| Fifty Day Average Change | 0.4173603 |
| Fifty Day Average Change Percent | 0.021757187 |
| Fifty Two Week Change Percent | -44.834255 |
| Fifty Two Week High | 48.45 |
| Fifty Two Week High Change | -28.85 |
| Fifty Two Week High Change Percent | -0.5954592 |
| Fifty Two Week Low | 16.36 |
| Fifty Two Week Low Change | 3.2399998 |
| Fifty Two Week Low Change Percent | 0.19804399 |
| Fifty Two Week Range | 16.36 - 48.45 |
| Financial Currency | CNY |
| First Trade Date Milliseconds | 1,737,729,000,000 |
| Float Shares | 71,058,342 |
| Forward Eps | -1.19 |
| Forward P E | -16.470589 |
| Free Cashflow | -942,630,656 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 767 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.91476 |
| Gross Profits | 525,182,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00056 |
| Implied Shares Outstanding | 93,337,216 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. |
| Market | us_market |
| Market Cap | 1,829,409,408 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_620569787 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,242,769,024 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,731,213,530 |
| Number Of Analyst Opinions | 9 |
| Open | 19.482 |
| Operating Cashflow | -1,174,128,000 |
| Operating Margins | -1.9335 |
| Payout Ratio | 0.0 |
| Phone | 86 512 8555 7777 |
| Post Market Change | -0.020000458 |
| Post Market Change Percent | -0.10193913 |
| Post Market Price | 19.6 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 19.97 |
| Price Eps Current Year | -12.927139 |
| Price Hint | 2 |
| Price To Book | 9.32314 |
| Price To Sales Trailing12 Months | 3.1864583 |
| Profit Margins | -2.16465 |
| Quick Ratio | 1.688 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | -0.36999893 |
| Regular Market Change Percent | -1.8527739 |
| Regular Market Day High | 19.62 |
| Regular Market Day Low | 19.482 |
| Regular Market Day Range | 19.482 - 19.62 |
| Regular Market Open | 19.482 |
| Regular Market Previous Close | 19.97 |
| Regular Market Price | 19.6 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 3,063 |
| Return On Assets | -0.23023 |
| Return On Equity | -1.54564 |
| Revenue Growth | 1.17 |
| Revenue Per Share | 6.448 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 93,337,216 |
| Shares Percent Shares Out | 0.0017 |
| Shares Short | 158,023 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,177 |
| Short Name | Ascentage Pharma Group Internat |
| Short Percent Of Float | 0.0021 |
| Short Ratio | 8.42 |
| Source Interval | 15 |
| Symbol | AAPG |
| Target High Price | 55.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 47.55556 |
| Target Median Price | 48.0 |
| Total Cash | 2,472,243,968 |
| Total Cash Per Share | 26.679 |
| Total Debt | 1,979,719,040 |
| Total Revenue | 574,120,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.331995 |
| Two Hundred Day Average Change | -6.7319946 |
| Two Hundred Day Average Change Percent | -0.25565836 |
| Type Disp | Equity |
| Volume | 3,063 |
| Website | https://www.ascentage.cn |
| Zip | 215,000 |